Publications by authors named "S J Kanes"
Article Synopsis
- - Major depressive disorder (MDD) can significantly impact a person's ability to function and traditional antidepressant treatments take weeks to show effects; zuranolone is a new oral treatment that's been approved for postpartum depression and is being studied for MDD.
- - The CORAL Study tested the effectiveness of zuranolone (50 mg) when combined with standard antidepressant therapy against a placebo in 425 adults with MDD, focusing on improvements in depression symptoms within the first three days.
- - Results showed that patients taking zuranolone experienced a greater reduction in depression scores by Day 3 compared to those on placebo, with mild to moderate side effects being the most common, such as drowsiness and headaches.
Article Synopsis
- * Patients in the zuranolone group experienced notable symptom relief as early as day 3, and this improvement was sustained through day 15 and beyond, with a statistically significant change from baseline scores.
- * The treatment was generally well tolerated, with similar rates of serious adverse events in both the zuranolone and placebo groups, suggesting its potential as a viable option for treating major depressive disorder.
A healthy stress response is critical for good mental and overall health and promotes neuronal growth and adaptation, but the intricately balanced biological mechanisms that facilitate a stress response can also result in predisposition to disease when that equilibrium is disrupted. The hypothalamic-pituitary-adrenal (HPA) axis neuroendocrine system plays a critical role in the body's response and adaptation to stress, and vasopressinergic regulation of the HPA axis is critical to maintaining system responsiveness during chronic stress. However, exposure to repeated or excessive physical or emotional stress or trauma can shift the body's stress response equilibrium to a "new normal" underpinned by enduring changes in HPA axis function.
View Article and Find Full Text PDFArticle Synopsis
- The MOUNTAIN study aimed to assess the effectiveness and safety of zuranolone, a new treatment for major depressive disorder (MDD), through a phase 3 trial involving adult outpatients.
- 581 participants were randomly assigned to receive either zuranolone (20 mg or 30 mg) or a placebo over 14 days, with improvements in depression symptoms measured primarily by the HDRS-17 scale.
- While the primary endpoint was not met, significant improvements in depressive symptoms were observed at days 3, 8, and 12 for the 30 mg zuranolone group, and the treatment was generally well tolerated with similar rates of side effects as the placebo group.
Article Synopsis
- Zuranolone, a treatment for postpartum depression (PPD), showed significant improvements in both anxiety and insomnia symptoms in women participating in a clinical study compared to a placebo.* -
- The study involved a double-blind, randomized trial with women aged 18-45 who had PPD, following treatment with either zuranolone or a placebo over a 14-day period.* -
- Results indicated higher rates of concurrent remission in depressive and anxiety symptoms with zuranolone, as well as positive effects on insomnia and overall functional health.*